A Observational Study to Evaluate Deucravacitinib in Patients With Moderate Plaque Psoriasis in China

A Prospective Observational Study to Evaluate the Effectiveness of Deucravacitinib in Patients With Moderate Plaque Psoriasis in Real-World Settings in China (ADMIRE)

The purpose of this study is to collect and evaluate real-world data on the effectiveness of deucravacitinib treatment in adults with moderate plaque psoriasis in China.

Inclusion Criteria:

• Participant aged 18 years or older
• Physician-reported (dermatologist) diagnosis of moderate plaque psoriasis with Body Surface Area ≥ 3% and < 10%
• Participant newly initiated deucravacitinib according to the label
• Provided written informed consent to participate in the study

Exclusion Criteria:

• Participating in or planning to participate in an interventional clinical trial
• Concomitant use of other systemic treatments for psoriasis at baseline
• Prior treatment of deucravacitinib